Lorlatinib

Summary

Lorlatinib (CHEMBL3286830) is an approved small-molecule antineoplastic agent (ATC L01ED05) targeting ALK, ROS1, and FES; indicated across 10 conditions including non-small cell lung carcinoma and neoplasm; with CIViC clinical evidence for 25 variant-indication associations (e.g. ALK Fusion in lung non-small cell carcinoma).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01ED05
• Targets: 3 (ALK, ROS1, FES)
• Indications: 10 conditions
• Clinical trials: 60
• Precision-oncology evidence (CIViC): 25 variant–indication associations
• Chemistry: 406.4 Da · C21H19FN6O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3286830
Name	Lorlatinib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	71731823
ChEBI	CHEBI:143117
ATC	L01ED05
Molecular formula	C21H19FN6O2
Molecular weight	406.4
InChIKey	IIXWYSCJSQVBQM-LLVKDONJSA-N

SMILES: C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C

IUPAC name: (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile

ChEBI definition: A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.

Pharmacological roles (ChEBI): antineoplastic agent, EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor.

Also known as: Lorbrena, Lorlatinib, Lorviqua, PF-06463922, LORLATINIB, NA, LORLATINIB_, lorlatinib

Parent form; salt/anhydrous children: CHEMBL4539157, CHEMBL6068047

Patent coverage: 1,575 distinct patent families (3,598 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 3,106 (86%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ALK	ALK receptor tyrosine kinase	Inhibition	9.15	0.8%	Q9UM73
ROS1	c-ros oncogene 1, receptor tyrosine kinase	Inhibition	11.3	0.1%	P08922
FES	FES proto-oncogene, tyrosine kinase	Inhibition	8.22	0.2%	P07332

Broader ChEMBL bioactivity targets: 24 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Epidermal growth factor receptor, 5-hydroxytryptamine receptor 1A, Acetylcholinesterase, Adenosine receptor A3, Focal adhesion kinase 1, High affinity nerve growth factor receptor, 3’,5’-cyclic-AMP phosphodiesterase 4D, Tyrosine-protein kinase JAK2, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 83 potent at pChembl ≥ 5 of 85 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ROS1	10	Ki	0.1	nM	CHEMBL_ACT_18761145
ROS1	10	Ki	0.1	nM	CHEMBL_ACT_22395851
SLC34A2	9.72	IC50	0.19	nM	CHEMBL_ACT_22424896
ALK	9.7	IC50	0.2	nM	CHEMBL_ACT_14722505
EML4	9.7	IC50	0.2	nM	CHEMBL_ACT_18761148
CD74	9.64	IC50	0.23	nM	CHEMBL_ACT_22424892
CD74	9.52	IC50	0.3	nM	CHEMBL_ACT_29238079
SLC34A2	9.4	IC50	0.4	nM	CHEMBL_ACT_29238047
ALK	9.15	Ki	0.7	nM	CHEMBL_ACT_14722369
ALK	9.15	Ki	0.7	nM	CHEMBL_ACT_18285545
ALK	9.15	Ki	0.7	nM	CHEMBL_ACT_18761156
ALK	9.15	Ki	0.7	nM	CHEMBL_ACT_22424890
ALK	9.15	Ki	0.7	nM	CHEMBL_ACT_25683778
ALK	8.89	IC50	1.3	nM	CHEMBL_ACT_14722560
EML4	8.89	IC50	1.3	nM	CHEMBL_ACT_18761147
ALK	8.89	IC50	1.3	nM	CHEMBL_ACT_24953979
ALK	8.8	IC50	1.6	nM	CHEMBL_ACT_14722507
EML4	8.8	IC50	1.6	nM	CHEMBL_ACT_18761149
LTK	8.57	IC50	2.7	nM	CHEMBL_ACT_14722558
LTK	8.57	Ki	2.7	nM	CHEMBL_ACT_24958176
FER	8.48	IC50	3.3	nM	CHEMBL_ACT_14722519
FER	8.48	Ki	3.3	nM	CHEMBL_ACT_24958172
ALK	8.38	IC50	4.2	nM	CHEMBL_ACT_14722511
EML4	8.38	IC50	4.2	nM	CHEMBL_ACT_18761151
ALK	8.26	IC50	5.5	nM	CHEMBL_ACT_28859399
ALK	8.26	IC50	5.5	nM	CHEMBL_ACT_28859453
ALK	8.26	IC50	5.5	nM	CHEMBL_ACT_28859459
ALK	8.26	IC50	5.5	nM	CHEMBL_ACT_28859465
ALK	8.26	IC50	5.5	nM	CHEMBL_ACT_28859471
ALK	8.26	IC50	5.5	nM	CHEMBL_ACT_28859477

Target pathways

Aggregated over 3 target gene(s): ALK, ROS1, FES.

Top Reactome pathways

21 total, by targets touching each:

Pathway	Targets	Genes
Signaling by SCF-KIT	1	FES
Signal Transduction	1	ALK
Disease	1	ALK
Signaling by ALK	1	ALK
Sema3A PAK dependent Axon repulsion	1	FES
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion	1	FES
CRMPs in Sema3A signaling	1	FES
Diseases of signal transduction by growth factor receptors and second messengers	1	ALK
Signaling by Receptor Tyrosine Kinases	1	ALK
Signaling by ALK in cancer	1	ALK
ALK mutants bind TKIs	1	ALK
Drug resistance of ALK mutants	1	ALK
ASP-3026-resistant ALK mutants	1	ALK
NVP-TAE684-resistant ALK mutants	1	ALK
alectinib-resistant ALK mutants	1	ALK
brigatinib-resistant ALK mutants	1	ALK
ceritinib-resistant ALK mutants	1	ALK
crizotinib-resistant ALK mutants	1	ALK
lorlatinib-resistant ALK mutants	1	ALK
Signaling by ALK fusions and activated point mutants	1	ALK
MDK and PTN in ALK signaling	1	ALK

Dominant GO biological processes

GO term	Targets
protein phosphorylation	3
signal transduction	2
cell surface receptor protein tyrosine kinase signaling pathway	2
regulation of cell population proliferation	2
protein autophosphorylation	2
response to stress	1
phosphorylation	1
hippocampus development	1
adult behavior	1
swimming behavior	1
peptidyl-tyrosine autophosphorylation	1
regulation of apoptotic process	1
regulation of neuron differentiation	1
neuron development	1
negative regulation of lipid catabolic process	1

Indications & clinical

Indications

10 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	4	MONDO:0005233	EFO:0003060
neoplasm	4	MONDO:0005070	EFO:0000616
lymphoma	4	MONDO:0005062	EFO:0000574
neuroblastoma	3	MONDO:0005072	EFO:0000621
ganglioneuroblastoma	3	MONDO:0005035	EFO:0000502
anaplastic large cell lymphoma	2	MONDO:0020325	EFO:0003032
lung neoplasm	2	MONDO:0021117	MONDO:0008903
kidney disorder	1	MONDO:0005240	EFO:0003086
liver disorder	1	MONDO:0005154	EFO:0001421

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 60.

Phase distribution

Phase	Trials
PHASE2	18
Not specified	18
PHASE1	11
PHASE4	5
PHASE1/PHASE2	4
PHASE3	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05144997	PHASE4	ACTIVE_NOT_RECRUITING	Lorlatinib Continuation Study
NCT06282874	PHASE4	ACTIVE_NOT_RECRUITING	Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
NCT06893354	PHASE4	NOT_YET_RECRUITING	Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
NCT04362072	PHASE4	COMPLETED	Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
NCT04541706	PHASE4	COMPLETED	Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
NCT03052608	PHASE3	ACTIVE_NOT_RECRUITING	A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03126916	PHASE3	RECRUITING	Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT06858410	PHASE3	NOT_YET_RECRUITING	Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
NCT02925234	PHASE2	RECRUITING	The Drug Rediscovery Protocol (DRUP Trial)
NCT04127110	PHASE2	ACTIVE_NOT_RECRUITING	Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients
NCT04621188	PHASE2	ACTIVE_NOT_RECRUITING	Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
NCT05297890	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05740943	PHASE2	ACTIVE_NOT_RECRUITING	Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
NCT06007937	PHASE1/PHASE2	RECRUITING	A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
NCT06378892	PHASE2	RECRUITING	A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
NCT06682884	PHASE2	NOT_YET_RECRUITING	Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer
NCT07083687	PHASE2	NOT_YET_RECRUITING	Lorlatinib in ROS1+ NSCLC With Brain Metastasis
NCT07415005	PHASE2	RECRUITING	Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
NCT01970865	PHASE1/PHASE2	COMPLETED	A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
NCT02584634	PHASE1/PHASE2	TERMINATED	Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
NCT02927340	PHASE2	UNKNOWN	A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
NCT03439215	PHASE2	UNKNOWN	PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer
NCT03505554	PHASE2	UNKNOWN	A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
NCT03612154	PHASE2	UNKNOWN	Study of Lorlatinib in ROS1 Rearranged NSCLC
NCT03737994	PHASE2	TERMINATED	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
NCT03909971	PHASE2	COMPLETED	A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
NCT04111705	PHASE2	COMPLETED	Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
NCT04292119	PHASE1/PHASE2	UNKNOWN	Lorlatinib Combinations in Lung Cancer
NCT05097599	PHASE2	TERMINATED	StrataPATH™ (Precision Indications for Approved Therapies)
NCT05948462	PHASE2	WITHDRAWN	Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
NCT02564562	PHASE1	COMPLETED	A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers
NCT02569554	PHASE1	COMPLETED	PPI And Food Effect Study For PF-06463922 In Healthy Volunteers
NCT02804399	PHASE1	COMPLETED	A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers
NCT02838264	PHASE1	COMPLETED	A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers
NCT03107988	PHASE1	COMPLETED	NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
NCT03542305	PHASE1	COMPLETED	Lorlatinib Renal Impairment Study
NCT03726333	PHASE1	TERMINATED	Hepatic Impairment Study for Lorlatinib in Cancer Patients
NCT03878524	PHASE1	TERMINATED	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
NCT03961997	PHASE1	COMPLETED	Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants
NCT04800822	PHASE1	TERMINATED	PF-07284892 in Participants With Advanced Solid Tumors

Clinical evidence (CIViC)

Variant × indication × effect (25 predictive associations from 28 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
ALK Fusion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Lorlatinib	CIViC A	EID11191 +3
ALK Mutation	Lung Non-small Cell Carcinoma	Sensitivity/Response	Lorlatinib	CIViC A	EID11286
ROS1 Fusion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Lorlatinib	CIViC B	EID11335
ALK Fusion	Inflammatory Myofibroblastic Tumor	Sensitivity/Response	Lorlatinib	CIViC C	EID11294
EML4::ALK Fusion AND ALK C1156Y	Lung Non-small Cell Carcinoma	Sensitivity/Response	Lorlatinib	CIViC C	EID842
EML4::ALK Fusion AND ALK I1171N AND ALK L1196M	Malignant Pleural Mesothelioma	Sensitivity/Response	Lorlatinib	CIViC C	EID11113
FN1::ALK Fusion	Inflammatory Myofibroblastic Tumor	Sensitivity/Response	Lorlatinib	CIViC C	EID11292
ROS1 S1986Y/F	Lung Non-small Cell Carcinoma	Sensitivity/Response	Lorlatinib	CIViC C	EID7689
TPM4::ALK Fusion	Inflammatory Myofibroblastic Tumor	Sensitivity/Response	Lorlatinib	CIViC C	EID11293
EML4::ALK Fusion AND ALK G1202R AND ALK I1171N AND ALK L1196M	Malignant Pleural Mesothelioma	Resistance	Lorlatinib	CIViC C	EID11114
EML4::ALK Fusion AND ALK G1202R AND ALK L1196M	Lung Non-small Cell Carcinoma	Resistance	Lorlatinib	CIViC C	EID7591
EML4::ALK Fusion AND ALK L1198F AND ALK C1156Y	Lung Non-small Cell Carcinoma	Resistance	Lorlatinib	CIViC C	EID843
ALK F1174L	Neuroblastoma	Sensitivity/Response	Lorlatinib	CIViC D	EID1329
ALK F1245C	Neuroblastoma	Sensitivity/Response	Lorlatinib	CIViC D	EID1330
ALK R1275Q	Neuroblastoma	Sensitivity/Response	Lorlatinib	CIViC D	EID1331
EML4::ALK Fusion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Lorlatinib	CIViC D	EID1332
EML4::ALK Fusion AND ALK G1202R	Cancer	Sensitivity/Response	Lorlatinib	CIViC D	EID7593
EML4::ALK Fusion AND ALK L1196M	Cancer	Sensitivity/Response	Brigatinib + Lorlatinib + Alectinib + Ceritinib	CIViC D	EID7597
GOPC::ROS1 e7::e35	Glioblastoma	Sensitivity/Response	Lorlatinib	CIViC D	EID7483
ROS1 G2032R AND v::ROS1 Fusion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Lorlatinib	CIViC D	EID1251
ROS1 L2026M AND CD74::ROS1 Fusion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Lorlatinib	CIViC D	EID1253
EML4::ALK Fusion AND ABCB1 Overexpression	Lung Adenocarcinoma	Resistance	Lorlatinib + Alectinib	CIViC D	EID10016
EML4::ALK Fusion AND ALK C1156Y	Cancer	Resistance	Lorlatinib + Alectinib + Ceritinib + Brigatinib	CIViC D	EID7609
EML4::ALK Fusion AND ALK G1202R AND ALK L1196M	Cancer	Resistance	Brigatinib + Crizotinib + Lorlatinib + Alectinib + Ceritinib	CIViC D	EID7592
EML4::ALK Fusion AND ALK G1202R AND ALK L1198F	Cancer	Resistance	Alectinib + Lorlatinib + Brigatinib + Ceritinib	CIViC D	EID7595

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

99 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
ALECTINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES, ROS1
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES, ROS1
ENTRECTINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES, ROS1
ERLOTINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES, ROS1
FEDRATINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES, ROS1
GILTERITINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES, ROS1
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES, ROS1
RUXOLITINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES, ROS1
BRIGATINIB	ChEMBL	Phase 4 (approved)	ALK, FES, ROS1
CERITINIB	ChEMBL	Phase 4 (approved)	ALK, FES, ROS1
NINTEDANIB	ChEMBL	Phase 4 (approved)	ALK, FES, ROS1
LESTAURTINIB	ChEMBL	Phase 3	ALK, FES, ROS1
BMS-754807	ChEMBL	Phase 2	ALK, FES, ROS1
FORETINIB	ChEMBL	Phase 2	ALK, FES, ROS1
R-406	ChEMBL	Phase 2	ALK, FES, ROS1
TOZASERTIB	ChEMBL	Phase 2	ALK, FES, ROS1
Afatinib	PubChem	Approved	ALK, FES, ROS1
Gefitinib	PubChem	Approved	ALK, FES, ROS1
Idelalisib	PubChem	Approved	ALK, FES, ROS1
Selumetinib	PubChem	Approved	ALK, FES, ROS1
BOSUTINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES
PALBOCICLIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES
REPOTRECTINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, ROS1
SUNITINIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES
VANDETANIB	ChEMBL + PubChem	Phase 4 (approved)	ALK, FES
INFIGRATINIB	ChEMBL	Phase 4 (approved)	ALK, ROS1
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	ALK, ROS1
LINIFANIB	ChEMBL	Phase 3	ALK, FES
ROCILETINIB	ChEMBL	Phase 3	ALK, FES
BI-2536	ChEMBL	Phase 2	ALK, FES
CENISERTIB	ChEMBL	Phase 2	ALK, ROS1
ILORASERTIB	ChEMBL	Phase 2	ALK, ROS1
OSI-632	ChEMBL	Phase 2	ALK, ROS1
PELITINIB	ChEMBL	Phase 2	ALK, FES
REBASTINIB	ChEMBL	Phase 2	FES, ROS1
SELITRECTINIB	ChEMBL	Phase 2	ALK, ROS1
belumosudil	PubChem	Approved	ALK, ROS1
Lapatinib	PubChem	Approved	FES, ROS1
Momelotinib	PubChem	Approved	FES, ROS1
Quizartinib	PubChem	Approved	FES, ROS1
Sorafenib	PubChem	Approved	FES, ROS1
AXITINIB	ChEMBL	Phase 4 (approved)	ROS1
DASATINIB	ChEMBL	Phase 4 (approved)	FES
LAROTRECTINIB	ChEMBL	Phase 4 (approved)	ROS1
MITOXANTRONE	ChEMBL	Phase 4 (approved)	ROS1
NERATINIB	ChEMBL	Phase 4 (approved)	FES
OSIMERTINIB	ChEMBL	Phase 4 (approved)	ALK
UPADACITINIB	ChEMBL	Phase 4 (approved)	ALK
ALISERTIB	ChEMBL	Phase 3	ROS1
ALVOCIDIB	ChEMBL	Phase 3	ALK
CANERTINIB	ChEMBL	Phase 3	ALK
CEDIRANIB	ChEMBL	Phase 3	ALK
DACTOLISIB	ChEMBL	Phase 3	ALK
DOVITINIB	ChEMBL	Phase 3	ALK
ENTOSPLETINIB	ChEMBL	Phase 3	ROS1
QUERCETIN	ChEMBL	Phase 3	ALK
RUBOXISTAURIN	ChEMBL	Phase 3	ROS1
SEMAXANIB	ChEMBL	Phase 3	ALK
BEMCENTINIB	ChEMBL	Phase 2	ALK
CEP-11981	ChEMBL	Phase 2	ALK